Evidence map›Paper›PMID 33014200›Full record

ArticleJournal of cardiology cases2020

A case in which SGLT2 inhibitor is a contributing factor to takotsubo cardiomyopathy and heart failure.

Haruyuki Kinoshita, Hiroshi Sugino, Toshiharu Oka, Orie Ichikawa, Takashi Shimonaga, Yoji Sumimoto, Ayano Kashiwabara, Takumi Sakai

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cardiology cases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Haruyuki KinoshitaDivision of Cardiology National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Kure, Japan.
Hiroshi SuginoDivision of Cardiology National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Kure, Japan.
Toshiharu OkaDivision of Cardiology National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Kure, Japan.
Orie IchikawaDivision of Cardiology National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Kure, Japan.
Takashi ShimonagaDivision of Cardiology National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Kure, Japan.
Yoji SumimotoDivision of Cardiology National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Kure, Japan.
Ayano KashiwabaraDivision of Cardiology National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Kure, Japan.
Takumi SakaiDivision of Cardiology National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Kure, Japan.
National Hospital Organization · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SGLT2 inhibitors are reported to have advantages in protecting against heart failure events. However, there are also reports of concerns when given to older persons or persons with geriatric syndrome. Our case is an example of a patient with a history of chronic thyroiditis where the SGLT2 inhibitor triggered a thyroid crisis, and blood catecholamine overload caused takotsubo cardiomyopathy and heart failure. <

Indexed as

Heart failureSGLT2 inhibitorTakotsubo cardiomyopathyThyroid crisis

Identifiers

PMID33014200
PMCPMC7520524
OpenAlexW3038717342

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.